The global epigenetics diagnostic market size is expected to reach USD 21.7 billion by 2026, expanding at a CAGR of 18.8% over the forecast period, according to a new study by Grand View Research, Inc. Growing prevalence of cancer and other diseases across the globe, along with epigenetic modification base, is anticipated to fuel the industry growth during the forecast period.
Diagnostic companies are upgrading their products by implementing new techniques for attaining specific and sensitive results. Companies such as Abcam plc, Invitrogen, and Sigma Aldrich Corporation are developing a new range of Chromatin immunoprecipitation (ChIP)-validated antibodies specific for detection of histone modifications at various loci.
In addition, many biotechnology and pharmaceutical companies and academic research organizations are collaborating to promote the growth of the epigenetics diagnostic industry. Companies such as Epigenomics, OncoMethylome Sciences, and Orion Genomics have collaborated with other laboratories and diagnostic companies that have licensed their technology for development of Laboratory-developed Tests (LDTs).
Technological advancements resulting in increased accuracy, portability, and cost-effectiveness are expected to be a high-impact rendering driver in the market. For instance, Diagenode has developed automated kits for detection and purification of methylated DNA.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
On the basis of product, reagents held the largest share owing to increasing R&D activities in field of epigenetics. Kits are expected to witness high demand over the forecast period, expanding at a CAGR of 19.2% due to need for rapid and accurate detection techniques
Based on technology, DNA methylation held a major share in terms of revenue in 2018. Technological advancements such as Methylation Sensitive PCR (MSP) and rapid adoption of these products to improve diagnostics efficiency are the factors attributing to its largest share
Growing prevalence of cancer with epigenetic modification is a key factor driving the oncology application segment. Solid tumors further dominated the segment in 2018
North America emerged as a major regional market in 2018 due to factors such as high levels of patient awareness, growing collaborations between large pharmaceutical firms for development of improved therapeutics, increasing funding for R&D, and increasing cancer prevalence
The market in Asia Pacific is estimated to witness significant growth over the forecast period with a CAGR of 20.9% owing to the presence of large target population having cancer, diabetes, and other chronic disorders, along with parallel unmet clinical needs
Major players of the industry include Sigma-Aldrich Corporation; Valirx Plc; Oncolys Biopharma Inc.; Zymo Research Corporation; Qiagen; Thermo Fisher Scientific; Diagenode Diagnostics; and Illumina, Inc. Extensive R&D initiatives for development of novel drugs and presence of strong product pipeline are expected to further boost the market growth over the forecast period.
Grand View Research has segmented the global epigenetics diagnostic market on the basis of product, technology, application, and region:
Epigenetics Diagnostic Product Outlook (Revenue, USD Million, 2014 - 2026)
ChIP Sequencing Kit
Whole Genomic Amplification Kit
Bisulfite Conversion Kit
RNA Sequencing Kit
Epigenetics Diagnostic Technology Outlook (Revenue, USD Million, 2014 - 2026)
Large non-coding RNA
Epigenetics Diagnostic Application Outlook (Revenue, USD Million, 2014 – 2026)
Epigenetics Diagnostic Regional Outlook (Revenue, USD Million, 2014 - 2026)
Middle East and Africa (MEA)
United Arab Emirates
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."